Phase I, Open Label Study Designed to Evaluate the Safety and Efficacy of a 1% Topical Formulation of KM-001 in the Treatment of Type I Punctate Palmoplantar Keratoderma or Pachyonychia Congenital Diseases
Latest Information Update: 10 Jan 2025
At a glance
- Drugs KM-001 (Primary)
- Indications Pachyonychia congenita; Palmoplantar keratoderma
- Focus Adverse reactions; Proof of concept
- Sponsors Kamari Pharma
Most Recent Events
- 07 Jan 2025 Status changed from recruiting to completed.
- 17 May 2024 According to Kamari Pharma media release, results of this trial presented at the 81st Annual Meeting of the Society for Investigative Dermatology (SID).
- 17 May 2024 Results published in the Kamari Media Release